Functional and structural analyses, particularly by Sarkar et al., showed that this variant reduces PCSK9's binding to LDL particles, enhancing LDL receptor degradation and producing an autosomal dominant FH phenotype [41, 42]. The gene discussed is LDLR; the disease is familial hyperaldosteronism.